VivoSeq
Other

MELAS

2

Pipeline Programs↗

1

Active Trials↗

3

Companies Involved↗

MELAS is an early-stage landscape with 2 programs across 3 companies. The most active players are Asklepion Pharmaceuticals, LLC, Santhera Pharmaceuticals, Thiogenesis Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Asklepion Pharmaceuticals, LLC

1 program

Phase 1S

Santhera Pharmaceuticals

1 program

Phase 2T

Thiogenesis Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 11

L-Citrulline

Asklepion Pharmaceuticals, LLC

Phase 21

Idebenone

Santhera Pharmaceuticals

Phase 3
No programs
Approved
No programs

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Completed1 · 50%

Clinical Trials

Trial Activity

A Study to Assess TTI-0102 vs Placebo in MELAS Patients
Recruiting·TThiogenesis Therapeutics, Inc.·Phase 2·NCT06644534·12 enrolled
L-Citrulline Dose Finding Safety Study in MELAS
Completed·—·Phase 1·NCT03952234·10 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)